Home Newsfeeds Seaport Global Downgrades Evergy to Neutral

Seaport Global Downgrades Evergy to Neutral

Seaport Global analyst Angie Storozynski downgrades Evergy (NYSE:EVRG) from Buy to Neutral.

byBenzinga Newsdesk

November 21, 2022

1 minute read

Seaport Global analyst Angie Storozynski downgrades Evergy (NYSE:EVRG) from Buy to Neutral.

Analyst Ratings

What 11 Analyst Ratings Have To Say About CVS Health

By Benzinga Insights

January 13, 12:00 PM

Over the past 3 months, 11 analysts have published their opinion on CVS Health (NYSE:CVS) stock. These analysts…

CVS

Avalon Globocare Has Received A Notice Of Allowance For Its U.S. Patent Application 17/210,837 Titled “Qty Fc Fusion Water Soluble Receptor Proteins (For The Treatment Of Cytokine Release Syndrome)”

By Benzinga Newsdesk

September 12, 11:32 AM

https://twitter.com/PatentGrants/status/1569347853348388864 https://patentcenter.uspto.gov/applications/17210837/ifw/docs

AVCO

Truist Securities Maintains Buy on Euronet Worldwide, Raises Price Target to $135

By Benzinga Newsdesk

January 20, 9:20 AM

Truist Securities analyst Andrew Jeffrey maintains Euronet Worldwide (NASDAQ:EEFT) with a Buy and raises the price target from $100 to $135.

EEFT

Pfizer/BioNTech’s Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages

By Vandana Singh

November 18, 1:03 PM

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced results from an analysis examining the immune response induced by their Omicron BA.4/BA.5-tailored bivalent COVID-19…

BNTX

Seaport Global Downgrades Evergy to Neutral

Related Posts

What 11 Analyst Ratings Have To Say About CVS Health

Avalon Globocare Has Received A Notice Of Allowance For Its U.S. Patent Application 17/210,837 Titled “Qty Fc Fusion Water Soluble Receptor Proteins (For The Treatment Of Cytokine Release Syndrome)”

Truist Securities Maintains Buy on Euronet Worldwide, Raises Price Target to $135

Pfizer/BioNTech’s Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages